PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30846365-0	2019	Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.	ARQ 197	18-28	epidermal growth factor receptor	Homo sapiens	132-136	
30846365-2	2019	Combining tivantinib, an inhibitor of the MET receptor tyrosine kinase, and cetuximab may be effective in patients with epidermal growth factor receptor-resistant MET-high mCRC.	ARQ 197	10-20	epidermal growth factor receptor	Homo sapiens	120-152	
26153496-14	2015	Although this study lacked statistical power because of the premature termination and did not demonstrate an improvement in OS, our results suggest that tivantinib plus erlotinib might improve PFS than erlotinib alone in nonsquamous NSCLC patients with WT-EGFR.	ARQ 197	153-163	epidermal growth factor receptor	Homo sapiens	256-260	
27843623-0	2016	Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib.	ARQ 197	33-43	epidermal growth factor receptor	Homo sapiens	102-106	
27843623-4	2016	This study evaluated the efficacy and safety of a c-Met selective inhibitor, tivantinib (ARQ 197), in combination with erlotinib, in Japanese EGFR mutation-positive patients with NSCLC who progressed while on EGFR-TKIs.	ARQ 197	77-87	epidermal growth factor receptor	Homo sapiens	142-146	
29288764-0	2018	Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study.	ARQ 197	0-10	epidermal growth factor receptor	Homo sapiens	68-72	
29288764-1	2018	INTRODUCTION: This exploratory subgroup analysis of the MARQUEE study evaluated the efficacy and safety of erlotinib plus tivantinib in patients with EGFR-mutant NSCLC.	ARQ 197	122-132	epidermal growth factor receptor	Homo sapiens	150-154	
29288764-9	2018	CONCLUSIONS: Erlotinib plus tivantinib was tolerable and showed improved efficacy over erlotinib monotherapy in previously treated EGFR-mutant NSCLC.	ARQ 197	28-38	epidermal growth factor receptor	Homo sapiens	131-135